Wiz cleared to complete $32 billion acquisition by Google-parent Alphabet

Cybersecurity company Wiz has received clearance from the U.S. Department of Justice for its $32 billion acquisition by Alphabet, marking the tech giant’s largest-ever purchase. Wiz will be integrated into Google Cloud, strengthening its cybersecurity offerings and enabling enterprises to better mitigate digital risk. The deal underscores growing strategic interest in cybersecurity as a differentiator in cloud services. Wiz is an underlying asset of VenCap 6, VenCap 10A, VenCap 13A, VenCap 13B, VenCap 15, VenCap 16, VenCap 17 and VenCap 18.

Decagon discusses new funding at $4–5 billion valuation

AI-powered customer service startup Decagon is reportedly in early talks to raise new equity funding at a valuation between $4 billion and $5 billion, up from $1.5 billion earlier this year. The San Francisco–based firm develops generative AI agents that automate customer interactions across voice, chat, and email, serving clients including Rippling and Duolingo. Backed by Bain Capital Ventures, Accel, and Andreessen Horowitz, Decagon is rapidly scaling, with annualised revenue exceeding $30 million, reflecting growing enterprise demand despite rising competition in the space. Decagon is an underlying asset of VenCap 6, VenCap 16, VenCap 17 and VenCap 18.

Hippocratic AI raises $126 million Series C at $3.5 billion valuation

Healthcare AI company Hippocratic AI has closed a $126 million Series C round at a $3.5 billion valuation, bringing total funding to $404 million. The round was led by Avenir Growth, with participation from CapitalG, General Catalyst, Andreessen Horowitz, and others. Hippocratic AI builds safety-focused generative AI healthcare agents, now deployed across 50+ health systems and payors in six countries, supporting over 115 million patient interactions. The new capital will expand customer deployments and fund continued product innovation centred on clinical safety and empathy. Hippocratic AI is an underlying asset of VenCap 16 and VenCap 17.

Synchron raises $200 million Series D at nearly $1 billion valuation Ventures

Neurotechnology firm Synchron has raised $200 million to advance its brain-computer interface technology, bringing its valuation close to $1 billion. The company’s Stentrode implant, inserted via blood vessels rather than open-brain surgery, aims to enable patients with paralysis or other disabilities to control computers by thought. The funding, led by Double Point Ventures with participation from IQT and other healthcare investors, will support clinical trials and development of next-generation devices capable of accessing multiple brain regions. Synchron is an underlying asset of VenCap 6, VenCap 13B, VenCap 15, VenCap 16 and VenCap 17.